Get all your news in one place.
100's of premium titles.
One app.
Start reading
Insider UK
Insider UK
Peter A Walker

Scottish biotech sets sights on Series A round and IPO

ICL Therapeutics has set its sights on a Series A funding round and an Initial Public Offering (IPO) following its most recent investment round.

The Motherwell-based biotech business claims to be on track to commercialise a suite of anti-viral medicines for the treatment of respiratory infections, including SARS-CoV-2.

ILC’s lead hybrid interferon drug, Alfacyte, is currently in development as an anti-viral medicine for the treatment of up-per respiratory tract viral infections, including the cause of Covid-19.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.